Prolonged IL-4 Treatment Decreases the Tnp-Specific Memory Formation for IgG1

  • René van Ommen
  • Huub F. J. Savelkoul
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 355)


IL-4 is a pleiotropic lymphokine, produced mainly by activated T-cells, which has a number of activities on B cells1. It is obligatory for IgE synthesis, and has an enhancing effect on the IgG1 production2. Whereas it is impossible to detect IgE in nematode infected mice which are made IL-4 deficient by gene targetting, IgG1 can be detected, but the level is only one-sixth that of control mice3. The aim of this study was to investigate the effect of prolonged IL-4 treatment on the total and antigen-specific serum IgG1 levels. Furthermore, we investigated the effect of such treatment on the memory formation for IgG1 To that end, BALB/c mice were treated for a period of three months with IL-4 after primary TNP-RIgG immunization. We used a method for cytokine administration that allowed persistent IL-4 levels for a prolonged period of time4.


Treated Mouse Control Treated Mouse Cytokine Administration CDC35 Cell Trinitrobenzenesulphonic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mosmann, T.R., and A. Zlotnik, Springer-Verlag Berlin Heidelberg. A. Habenicht (Ed.); 229 (1990).Google Scholar
  2. 2.
    Finkelman, F. D., J. Holmes, I.M. Katona, J.F. Uraban, M.P. Beckman, L.S. Park, K.A. Schooley, R.L. Coffman, T.R. Mosmann, and W.E. Paul, Annu. Rev. Immunol. 8:303 (1990).PubMedCrossRefGoogle Scholar
  3. 3.
    Kuhn, R., K. Rajewsky, and W. Muller, Science 254:707 (1991).PubMedCrossRefGoogle Scholar
  4. 4.
    Savelkoul, H.F.J., B.W.P. Seymour, L. Sullivan, and R.L. Coffman, J. Immunol. 146:1801 (1991).PubMedGoogle Scholar
  5. 5.
    VanOmmen, R., A.E.C.M. Vredendaal, and H.F.J. Savelkoul, Submitted for publication.Google Scholar
  6. 6.
    Tony, H.P., and D.C. Parker, J. Exp. Med. 161:223 (1985).PubMedCrossRefGoogle Scholar
  7. 7.
    Snapper, CM., F.D. Finkelman, D. Stefany, D.H. Conrad, and W.E. Paul. J. Immunol. 141:489 (1988).PubMedGoogle Scholar
  8. 8.
    Yoshida, K., M. Matsuoka, S. Usuda, A. Mori, K. Ishizaka, and H. Sakano. Proc. Natl. Acad. Sci. USA. 87:7829 (1990).PubMedCrossRefGoogle Scholar
  9. 9.
    Mandler, R., F.D. Finkelman, A.D. Levine, and C.M. Snapper. J. Immunol. 150:407 (1993).PubMedGoogle Scholar
  10. 10.
    Harriman, W., H. Volk, N. Defranoux, and M. Wabl. Annu. Rev. Immunol. 11:361 (1993).PubMedCrossRefGoogle Scholar
  11. 11.
    Croft, M., and S.L. Swain, J. Immunol. 146:4055 (1991).PubMedGoogle Scholar
  12. 12.
    Hodgkin, P.D., N.F. Go, J.E. Cupp, and M. Howard, Cell. Immunol. 134:14 (1991).PubMedCrossRefGoogle Scholar
  13. 13.
    Sinclair, N.R.StC, and A. Panoskaltsis, 1988. Curr. Opin. in Immunol. 1:228 (1988).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • René van Ommen
    • 1
  • Huub F. J. Savelkoul
    • 1
  1. 1.Department of Immunology ErasmusUniversity RotterdamThe Netherlands

Personalised recommendations